The federal government has announced that Nigeria will receive its first shipment of Lenacapavir, a revolutionary twice-yearly injectable HIV prevention drug, in March 2026.
The National Agency for the Control of AIDS (NACA) made this exciting disclosure in a statement released on Monday, March 2, signaling a major breakthrough in Nigeria’s fight against HIV/AIDS.
What Makes Lenacapavir Special?
Unlike traditional HIV prevention methods that require daily pills, Lenacapavir is a long-acting injectable drug that only needs to be administered twice a year. This means Nigerians at risk of HIV infection will only need to visit healthcare facilities every six months for protection.
Clinical trials have shown remarkable results—Lenacapavir significantly reduces the risk of HIV infection and provides almost complete protection against the virus. This could be a game-changer for millions of Nigerians, particularly those in high-risk groups.
Government’s Strategic Rollout Plan
NACA emphasized that the introduction of Lenacapavir as Pre-Exposure Prophylaxis (PrEP) demonstrates the federal government’s commitment to strengthening HIV prevention and accelerating progress toward controlling the epidemic in Nigeria.
“The Government of Nigeria is advancing preparations for the introduction and rollout of Lenacapavir as Pre-Exposure Prophylaxis. This is part of Government’s commitment to strengthen HIV prevention and accelerate progress toward epidemic control,” the agency stated.
The rollout will be carefully phased and quality-assured, with coordinated efforts across priority states to ensure proper implementation.
Which States Will Receive It First?
NACA has already completed landscape and readiness assessments in 10 states to evaluate service delivery capacity and identify what each location needs for successful implementation. These states include:
– Akwa Ibom
– Anambra
– Benue
– Cross River
– Ebonyi
– Federal Capital Territory (FCT)
– Gombe
– Kano
– Kwara
– Lagos
Preparations Already Underway
The federal government isn’t waiting until the drug arrives to prepare. NACA has already:
– Conducted a national training of trainers in Abuja
– Organized step-down training sessions for healthcare workers in selected states
– Developed information, education, and communication (IEC) materials to raise awareness among Nigerians
These preparations ensure that when Lenacapavir arrives in March 2026, trained healthcare personnel will be ready to administer it properly, and communities will already be informed about this new prevention option.
What This Means for Nigeria
With Nigeria having one of the highest HIV burdens in the world, the introduction of Lenacapavir represents a significant step forward in public health. The convenience of a twice-yearly injection could dramatically improve adherence rates compared to daily pills, potentially preventing thousands of new infections.
This development also demonstrates Nigeria’s commitment to adopting innovative healthcare solutions and ensuring that our citizens have access to the latest medical advancements in HIV prevention.
As we await the arrival of this groundbreaking drug, healthcare advocates encourage Nigerians to continue practicing safe behaviours and utilizing existing HIV prevention methods.
The rollout of Lenacapavir is backed by regulatory approval, system preparedness, trained personnel, and comprehensive community engagement strategies, positioning Nigeria at the forefront of HIV prevention innovation in Africa.
For More Information, Visit Buzzup9ja
Be the first to comment